We therefore selected a sub-group of patients with the 10 highest individual anti-ApoB IgG levels with clinical obesity and hypertension (“high” CVD risk) and with the 10 lowest individual anti-ApoB IgG levels without clinical obesity and hypertension (“low” CVD risk). This evidence concerns the gene APOB and Obesity.